Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Geron Corporation (GERN) Guidance & Earnings Results

On 2026-08-06 Geron Corporation reaffirmed guidance: "FY2026 RYTELO revenue $220-240M; operating expenses…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

GERNGeron CorporationFollow GERN — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
719.6M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
4 Nov, in 11 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
6 Aug 26ReaffirmedFY2026 RYTELO revenue $220-240M; operating expenses $230-240M · full year
25 Feb 26Reaffirmed2026 RYTELO revenue $220M-$240M; opex $230M-$240M · full year
6 Aug 25ReaffirmedFY2025 total operating expenses $270-285M · full year

Geron Corporation — questions

What guidance did Geron Corporation give?
On 2026-08-06: "FY2026 RYTELO revenue $220-240M; operating expenses $230-240M"
When does Geron Corporation report earnings?
Geron Corporation's next earnings report is expected on 2026-11-04.

Every figure on this page comes from Geron Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.